Skip to main content
Log in

Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Purpose

The objective of this study is to determine the range of SUVmax of 68Ga-DOTATATE in normal organs and tumoral lesions and establish uptake unrelated to NET.

Materials and methods

One hundred and twenty patients (57 men, 63 women), who underwent 68Ga-DOTATATE PET/CT imaging in our institution were analyzed. Patients were indicated for 68Ga-DOTATATE PET/CT imaging to detect primary tumor or metastasis of suspected or previously known NET, to determine SSTR positivity and to detect occult source of ectopic Cushing syndrome. Normal range of uptake was calculated for the organs that were proven to have no pathology by either conventional radiological imaging or clinical follow-up, using SUVmax as a semiquantitative measure. Uptake and tumor to background (T/B) ratios of tumoral lesions in liver, pancreas, bone, brain and lymph nodes were calculated. Uptakes due to lesions unrelated to NET were also documented.

Results

Significant uptake was found in spleen, kidneys, adrenal glands, liver and pituitary gland with mean SUVmax of 24.67, 14.30, 13.73, 9.12 and 9.74 respectively. Uptake was measured separately for the pancreatic head and body separately, however, besides a slightly heterogeneous uptake; the difference was not statistically significant. Uptake in the tumoral lesions had high (T/B) ratios with mean SUVmax of 28.72, 25.21, 18.28, 34.73 and 12.59 for liver, pancreas, bone, brain and lymph nodes, respectively. Incidental benign tumoral lesions were detected in 3 patients (2.5 %) which were meningioma and fibrous dysplasia demonstrating significant and breast fibroadenoma demonstrating mild 68Ga-DOTATATE uptake. Non-neoplastic processes were detected in 4 patients (14.1 %), including postsurgical inflammation, reactive lymph nodes, arthritis and demonstrated faint to mild 68Ga-DOTATATE uptake, with the exception of significant uptake in accessory spleen.

Conclusion

68Ga-DOTATATE has high T/B ratio with physiological biodistribution comparable to its counterparts. However, the presence of SSTRs in benign and malignant lesions unrelated to NET may be challenging in interpretation particularly where the physiological uptake is variable.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Blom E, Koziorowski J. 68Ga-autoclabeling of DOTA-TATE and DOTA-NOC. Appl Radiat Isot. 2012;70:980–3.

    Article  PubMed  CAS  Google Scholar 

  2. Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in NET: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.

    Article  PubMed  Google Scholar 

  3. Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]- DOTA-D Phe(1)-Tyr(3)-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with NET. Mol Imaging Biol. 2003;5:42–8.

    Google Scholar 

  4. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP. NET. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab. 2007;21:111–29.

    Article  PubMed  CAS  Google Scholar 

  5. Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.

    Article  PubMed  CAS  Google Scholar 

  6. Kunikowska J, Królicki L, Pawlak D, Zerizer I, Mikołajczak R. Semiquantitative Analysis and Characterization of Physiological Biodistribution of 68Ga-DOTATATE PET/CT. Clin Nucl Med. 2012;37(11):1052–7.

    Article  PubMed  Google Scholar 

  7. Kuyumcu S, Adalet I, Sanli Y, Turkmen C, Ozkan ZG, Yilmazbayhan D. Somatostatin receptor scintigraphy with (111)In-octreotide in pulmonary carcinoid tumors correlated with pathological and (18)FDG PET/CT findings. Ann Nucl Med. 2012;26(9):689–97.

    Article  PubMed  CAS  Google Scholar 

  8. Buchmann I, Henze M, Engelbrecht S, Buchmann I, Henze M, Engelbrecht S, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (OctreoScan) SPECT in patients with NET. Eur J Nucl Med Mol Imaging. 2007;34:1617–26.

    Article  PubMed  CAS  Google Scholar 

  9. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T, et al. Functional imaging of NET with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe(1), Tyr(3)-octreotate) and 18F-FDG. Cancer. 2008;112:2447–55.

    Article  PubMed  Google Scholar 

  10. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTATyr3-octreotide PET in NET: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48:508–18.

    Article  PubMed  CAS  Google Scholar 

  11. Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumors: (68)Ga-DOTA (0), Tyr (3)-octreotide versus (68)Ga-DOTA (0)-lanreotide. Eur J Nucl Med Mol Imaging. 2012. doi:10.1007/s00259-012-2286-6.

    Google Scholar 

  12. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of NET. J Nucl Med. 2011;52(12):1864–70.

    Article  PubMed  CAS  Google Scholar 

  13. Zamora V, Cabanne A, Salanova R, Bestani C, Domenichini E, Marmissolle F, et al. Immunohistochemical expression of somatostatin receptors in digestive endocrine tumors. Dig Liver Dis. 2010;42:220–5.

    Article  PubMed  CAS  Google Scholar 

  14. Pepe G, Moncayo R, Bombardieri E, Chiti A. Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging. 2012;39(Suppl 1):S41–51.

    Article  PubMed  Google Scholar 

  15. Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, et al. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in NET. Eur J Nucl Med Mol Imaging. 2011;38:1659–68.

    Article  PubMed  CAS  Google Scholar 

  16. Srirajaskanthan R, Kayani I, Quigley AM, Soh J, Caplin ME, Bomanji J. The role of 68Ga-DOTATATE PET in patients with NET and negative or equivocal findings on 111In-DTPA-octreotide scintigraphy. J Nucl Med. 2010;51(6):875–82.

    Article  PubMed  CAS  Google Scholar 

  17. Haug AR, Cindea-Drimus R, Auernhammer CJ, Reincke M, Wängler B, Uebleis C, et al. The role of 68Ga-DOTATATE PET/CT in suspected NET. J Nucl Med. 2012;53(11):1686–92.

    Article  PubMed  CAS  Google Scholar 

  18. Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with NET. Eur J Nucl Med Mol Imaging. 2012;39(8):1271–7.

    Article  PubMed  Google Scholar 

  19. Boy C, Heusner TA, Poeppel TD, Redmann-Bischofs A, Unger N, Jentzen W, et al. 68Ga-DOTATOC PET/CT and somatostatin receptor (sst1-sst5) expression in normal human tissue: correlation of sst2 mRNA and SUVmax. Eur J Nucl Med Mol Imaging. 2011;38(7):1224–36.

    Article  PubMed  CAS  Google Scholar 

  20. Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun. 2010;31(12):1025–32.

    PubMed  Google Scholar 

  21. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with NET: characterization of uptake in normal organs and tumor lesions. Q J Nucl Med Mol Imaging. 2010;54(1):61–7.

    PubMed  CAS  Google Scholar 

  22. Krausz Y, Rubinstein R, Appelbaum L, Mishani E, Orevi M, Fraenkel M, et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin Nucl Med. 2012;37(1):57–62.

    Article  PubMed  Google Scholar 

  23. Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC, et al. Incidence of increased 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J Nucl Med. 2011;52(6):886–90.

    Article  PubMed  Google Scholar 

  24. Hofmann M, Maecke H, Börner R, Weckesser E, Schöffski P, Oei L, et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data. Eur J Nucl Med. 2001;28(12):1751–7.

    Article  PubMed  CAS  Google Scholar 

  25. Schulz S, Pauli SU, Schulz S, Händel M, Dietzmann K, Firsching R, et al. Immunohistochemical determination of five somatostatin receptors in meningioma reveals frequent overexpression of somatostatin receptor subtype sst2A. Clin Cancer Res. 2000;6(5):1865–74.

    PubMed  CAS  Google Scholar 

  26. Inanir S, Unlu M, Okudan B, Cila E, Atik S. Indium-111 octreotide scintigraphy in patients with bone tumours of the extremities. Eur J Nuc Med. 1996;23:987–90.

    Article  CAS  Google Scholar 

  27. Chen CC, Czerwiec FS, Feuillan PP. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy. J Nucl Med. 1998;39(2):238–40.

    PubMed  CAS  Google Scholar 

Download references

Conflict of interest

The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Serkan Kuyumcu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kuyumcu, S., Özkan, Z.G., Sanli, Y. et al. Physiological and tumoral uptake of 68Ga-DOTATATE: standardized uptake values and challenges in interpretation. Ann Nucl Med 27, 538–545 (2013). https://doi.org/10.1007/s12149-013-0718-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-013-0718-4

Keywords

Navigation